HALOZYME THERAPEUTICS, INC.
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2025, the following officer adopted Rule 10b5-1 trading arrangements (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Title | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares To Be Sold | Expiration Date |
| Bernadette Connaughton | Adoption | 5/29/2025 | X | 17,330 | 8/31/2026 | |
| Director | ||||||
| Nicole LaBrosse | Adoption | 6/11/2025 | X | 39,337 | *** | 4/22/2026 |
| Senior Vice President and Chief Financial Officer | ||||||
- Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act.
*** The total number of shares to be sold under this plan is 22,227 plus an undetermined number of shares to be sold resulting from the vesting of 17,110 restricted stock units less the amount of shares that will be withheld to satisfy the payment of tax withholding obligations due upon vesting.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.